INCYTE PHARMACEUTICALS, INC. v. Affymetrix, Inc.

Good Law
131 F. Supp. 2d 1154·2000 WL 33245468·2000 U.S. Dist. LEXIS 20571
United States District Court, Northern District of CaliforniaSeptember 8, 2000C 99-21111 JF EAICalifornia1,729 words

Opinion

Opinion

Fogel, J.

ORDER DENYING MOTION TO DISMISS

Defendant Affymetrix, Inc. (“Affyme-trix”), moves for dismissal of the first amended complaint for lack of subject-matter jurisdiction pursuant to Federal Rule of Civil Procedure 12(b)(1). Plaintiffs Incyte Pharmaceuticals, Inc. (“Incyte”), and the Board of Trustees of the Leland Stanford Junior University (“Stanford”) oppose the motion. The Court has read the moving and responding papers and has considered the oral arguments of counsel presented on July 10, 2000. For the reasons set forth below, the motion will be denied.

I. BACKGROUND

In March 1995, Stanford and Synteni, Inc. (“Synteni”), entered into an agreement whereby Stanford granted Synteni an exclusive license to make, use and sell products covered by, inter alia, certain patents and patent applications. Stanford also granted Synteni the right to grant sublicenses at its discretion and without consent from Stanford. Both Stanford and Synteni had the right to institute infringement actions involving licensed patents, but each was required to provide notice to the other, which had the option to join in the proceedings.

In August 1995, Patrick Brown and Dari Shalon (“Brown et al.”) filed…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.